Proteasome inhibitors are a novel class of compounds that might increase sensitivity to
chemotherapy for acute myeloid leukemia (AML). We quantified apoptosis in THP-1 cells …

The chimeric oncogene bcr-abl is detected in virtually every case of chronic myelogenous
leukemia. It has been shown that cells (such as K562) expressing Bcr-Abl/p210, a protein …

The proteasome plays a critical role in the regulation of many cellular processes, including
the cell cycle and tumor growth. The proteasome inhibitor bortezomib has recently been …

Bortezomib is a highly selective inhibitor of the 26S proteasome and has been approved for
clinical use in the treatment of relapsing and refractory multiple myeloma and mantle cell …

The multiple cellular targets affected by proteasome inhibition implicate a potential role for
bortezomib, a first-in-class proteasome inhibitor, in enhancing antitumor activities in …

The sustained cytotoxicity conferred by proteasome inhibitors against a broad spectrum of
human cancer cells is mediated by a delicate mechanism of programmed cell death. Similar …

The proteasome has been successfully targeted for the treatment of multiple myeloma and
mantle cell lymphoma; however, in other hematologic malignancies, bortezomib has been …

Proteasome inhibitors display potent anti-neoplastic and anti-angiogenic properties both in
vitro and in vivo. The mechanisms, however, by which proteasome inhibitors kill tumor cells …

Purpose Previously, compounds containing a piperidone structure have been shown to be
highly cytotoxic to cancer cells. Recently, we found that the piperidone compound P2 …

Purpose: Bortezomib is a peptide boronic acid inhibitor of the proteasome developed for
cancer therapy. The compound is being evaluated currently in Phase II and III clinical trials …